MedTrace Logo

Development of a Quantitative Tissue Optical Index of Breast Density For Prediction of Hormone Therapy Response

NCT01773551 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-11-02

No results posted yet for this study

Summary

The purpose of this research study is to investigate whether breast density measured by a safe, painless imaging method (called Diffuse Optical Spectroscopic Imaging - DOSI) can detect the decrease of breast density in subjects who receive tamoxifen when compared to patients who do not receive any drug. If decreased density can be reliably detected, it may help determine which subjects will benefit by taking tamoxifen or other chemoprevention drugs.

Conditions

  • Accessory; Breast Tissue

Interventions

OTHER

Breast Density

Development of a Quantitative Tissue Optical Index of Breast Density

Sponsors & Collaborators

Principal Investigators

  • Thomas O' Sullivan, PhD · Beckman Laser Institute, UCI

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01773551 on ClinicalTrials.gov